On August 1, the Centers for Medicare and Medicaid Services
("CMS") released its Inpatient Prospective Payment System
("IPPS") final rule. Included in the rule was the initial
framework for the Hospital Readmission Reduction Program (the
"HRRP") which is set to begin in the 2013 fiscal year.
The HRRP, unlike the inpatient quality reporting program currently
in place, will penalize hospitals with high readmission rates for
In keeping with an effort to reduce costs and improve
coordination of patient care, the Patient Protection and Affordable
Care Act (the "Act") established the HRRP by adding a new
subsection (q) to section 1886 of the Social Security Act.
Beginning October 1, 2012, the HRRP will lower payment rates for
all Medicare discharges if acute care hospitals experience
higher-than-average readmission rates for certain "applicable
conditions." The program will begin with three applicable
conditions: acute myocardial infarction ("AMI"), heart
failure, and pneumonia. In the final rule, CMS explained that of
the 235 diagnostic categories for hospitalization it reviewed,
heart failure and pneumonia were the first and second most frequent
category for both total admissions and readmissions, and AMI ranked
ninth in frequency of admission and eighth in frequency of
For the first two years of the program, AMI, heart failure, and
pneumonia will be the only applicable conditions on which
readmission rates will be calculated. Beginning in 2015, however,
CMS will add additional conditions or procedures it believes
represent high costs and high volumes of readmission. For the
purposes of the rule, "readmission" occurs when a patient
is discharged to a non-acute setting (for example, home health,
skilled nursing, rehabilitation facilities, or the patient's
home) and is subsequently readmitted or admitted to another acute
care hospital within 30 days of discharge.
CMS will calculate baseline readmission rates using data from
July 1, 2008 to June 30, 2011, and underperforming hospitals will
see a reduction in reimbursements. For the first year of the
program, payment reductions will be capped at a maximum of one
percent of inpatient payments. The payment reduction rates will
subsequently increase by one percent each year before being capped
at three percent for fiscal year 2015 and beyond.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
It's been a couple of months since the dust has settled from FDA's October 26, 2016 approval of Mylan Pharmaceuticals Inc.'s ANDA 078276 for a generic version of Daiichi Sankyo Inc.'s BENICAR Tablets...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).